Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review

Dorene M Rentz, Mario A Parra Rodriguez, Rebecca Amariglio, Yaakov Stern, Reisa Sperling, Steven Ferris

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer's disease is during the preclinical phase of the disease. This is a phase when individuals are defined as clinically normal but exhibit evidence of amyloidosis, neurodegeneration and subtle cognitive/behavioral decline. While our standard cognitive tests are useful for detecting cognitive decline at the stage of mild cognitive impairment, they were not designed for detecting the subtle cognitive variations associated with this biomarker stage of preclinical Alzheimer's disease. However, neuropsychologists are attempting to meet this challenge by designing newer cognitive measures and questionnaires derived from translational efforts in neuroimaging, cognitive neuroscience and clinical/experimental neuropsychology. This review is a selective summary of several novel, potentially promising, approaches that are being explored for detecting early cognitive evidence of preclinical Alzheimer's disease in presymptomatic individuals.
LanguageEnglish
Number of pages10
JournalAlzheimer's research & therapy
Volume5
Issue number6
DOIs
Publication statusPublished - 21 Nov 2013

Fingerprint

Alzheimer Disease
Neuropsychology
Amyloidosis
Neuroimaging
Biomarkers
Guidelines
Cognitive Dysfunction
Cognitive Neuroscience
Surveys and Questionnaires

Keywords

  • mild cognitive impairment
  • default mode network
  • cerebral spinal fluid
  • cognitive reserve
  • pattern separation
  • neuropsychological
  • Alzheimer’s disease

Cite this

@article{a81ece987487426fa6a99a24fecdbdfa,
title = "Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review",
abstract = "Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer's disease is during the preclinical phase of the disease. This is a phase when individuals are defined as clinically normal but exhibit evidence of amyloidosis, neurodegeneration and subtle cognitive/behavioral decline. While our standard cognitive tests are useful for detecting cognitive decline at the stage of mild cognitive impairment, they were not designed for detecting the subtle cognitive variations associated with this biomarker stage of preclinical Alzheimer's disease. However, neuropsychologists are attempting to meet this challenge by designing newer cognitive measures and questionnaires derived from translational efforts in neuroimaging, cognitive neuroscience and clinical/experimental neuropsychology. This review is a selective summary of several novel, potentially promising, approaches that are being explored for detecting early cognitive evidence of preclinical Alzheimer's disease in presymptomatic individuals.",
keywords = "mild cognitive impairment, default mode network, cerebral spinal fluid, cognitive reserve, pattern separation, neuropsychological, Alzheimer’s disease",
author = "Rentz, {Dorene M} and {Parra Rodriguez}, {Mario A} and Rebecca Amariglio and Yaakov Stern and Reisa Sperling and Steven Ferris",
year = "2013",
month = "11",
day = "21",
doi = "10.1186/alzrt222",
language = "English",
volume = "5",
journal = "Alzheimer's research & therapy",
issn = "1758-9193",
number = "6",

}

Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease : a selective review. / Rentz, Dorene M; Parra Rodriguez, Mario A; Amariglio, Rebecca; Stern, Yaakov; Sperling, Reisa; Ferris, Steven.

In: Alzheimer's research & therapy, Vol. 5, No. 6, 21.11.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease

T2 - Alzheimer's research & therapy

AU - Rentz, Dorene M

AU - Parra Rodriguez, Mario A

AU - Amariglio, Rebecca

AU - Stern, Yaakov

AU - Sperling, Reisa

AU - Ferris, Steven

PY - 2013/11/21

Y1 - 2013/11/21

N2 - Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer's disease is during the preclinical phase of the disease. This is a phase when individuals are defined as clinically normal but exhibit evidence of amyloidosis, neurodegeneration and subtle cognitive/behavioral decline. While our standard cognitive tests are useful for detecting cognitive decline at the stage of mild cognitive impairment, they were not designed for detecting the subtle cognitive variations associated with this biomarker stage of preclinical Alzheimer's disease. However, neuropsychologists are attempting to meet this challenge by designing newer cognitive measures and questionnaires derived from translational efforts in neuroimaging, cognitive neuroscience and clinical/experimental neuropsychology. This review is a selective summary of several novel, potentially promising, approaches that are being explored for detecting early cognitive evidence of preclinical Alzheimer's disease in presymptomatic individuals.

AB - Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer's disease is during the preclinical phase of the disease. This is a phase when individuals are defined as clinically normal but exhibit evidence of amyloidosis, neurodegeneration and subtle cognitive/behavioral decline. While our standard cognitive tests are useful for detecting cognitive decline at the stage of mild cognitive impairment, they were not designed for detecting the subtle cognitive variations associated with this biomarker stage of preclinical Alzheimer's disease. However, neuropsychologists are attempting to meet this challenge by designing newer cognitive measures and questionnaires derived from translational efforts in neuroimaging, cognitive neuroscience and clinical/experimental neuropsychology. This review is a selective summary of several novel, potentially promising, approaches that are being explored for detecting early cognitive evidence of preclinical Alzheimer's disease in presymptomatic individuals.

KW - mild cognitive impairment

KW - default mode network

KW - cerebral spinal fluid

KW - cognitive reserve

KW - pattern separation

KW - neuropsychological

KW - Alzheimer’s disease

U2 - 10.1186/alzrt222

DO - 10.1186/alzrt222

M3 - Article

VL - 5

JO - Alzheimer's research & therapy

JF - Alzheimer's research & therapy

SN - 1758-9193

IS - 6

ER -